tag:blogger.com,1999:blog-57817091107779708312024-03-13T20:52:28.994-07:00Lindsay RosenwaldInsight, news, and general discussion from prominent investor and health care specialist Lindsay Rosenwald Lindsay Rosenwaldhttp://www.blogger.com/profile/05813621454692272361noreply@blogger.comBlogger14125tag:blogger.com,1999:blog-5781709110777970831.post-28753896958198360742014-09-30T15:48:00.001-07:002014-09-30T15:48:42.885-07:00The Three Clinical Phases of Drug Discovery<div dir="ltr" style="text-align: left;" trbidi="on">
Clinical trials represent some of the most important and widely recognized stages of the drug discovery process. Here is a quick look at the three primary stages of clinical trials.<br /><br />Phase 1: Phase 1 clinical trials involve the first human testing in the entire life cycle of a potential drug. The trials occur in a small group of healthy volunteers and typically address questions involving absorption into the body, metabolism of the substance, and the presence of side effects. <br /><br />Phase 2: After a drug passes through Phase 1, researchers expand clinical trials to include a small group of patients with the disease or condition in question. In Phase 2 clinical trials, scientists gather valuable data on the efficacy of the drug, the mechanism by which it proceeds, and the optimal dosage and scheduling.<br /><br />Phase 3: In the final stage of clinical trials, researchers again expand the study to include anywhere between 1,000 and 5,000 patients. In Phase 3 trials, researchers conduct further investigation of safety and efficacy and hone in on appropriate labeling for the compound.</div>
Lindsay Rosenwaldhttp://www.blogger.com/profile/05813621454692272361noreply@blogger.com0tag:blogger.com,1999:blog-5781709110777970831.post-48684865206986639152014-04-30T12:03:00.002-07:002014-04-30T12:03:25.233-07:00An Overview of Rheumatoid Arthritis<div class="separator" style="clear: both; text-align: center;">
<span style="color: #0c343d;"><a href="http://static.imt.ie/wp-content/uploads/2013/02/arthritis1.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="http://static.imt.ie/wp-content/uploads/2013/02/arthritis1.jpg" height="212" width="320" /></a></span></div>
<span style="color: #0c343d;"><br /></span>
<hr />
<!--[if gte mso 9]><xml>
<w:WordDocument>
<w:View>Normal</w:View>
<w:Zoom>0</w:Zoom>
<w:Compatibility>
<w:BreakWrappedTables/>
<w:SnapToGridInCell/>
<w:WrapTextWithPunct/>
<w:UseAsianBreakRules/>
</w:Compatibility>
<w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel>
</w:WordDocument>
</xml><![endif]--><br />
<!--[if !mso]><img src="//img2.blogblog.com/img/video_object.png" style="background-color: #b2b2b2; " class="BLOGGER-object-element tr_noresize tr_placeholder" id="ieooui" data-original-id="ieooui" />
<style>
st1\:*{behavior:url(#ieooui) }
</style>
<![endif]--><!--[if gte mso 10]>
<style>
/* Style Definitions */
table.MsoNormalTable
{mso-style-name:"Table Normal";
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-parent:"";
mso-padding-alt:0in 5.4pt 0in 5.4pt;
mso-para-margin:0in;
mso-para-margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-size:10.0pt;
font-family:"Times New Roman";}
</style>
<![endif]--><span style="color: #0c343d;"><span style="font-family: "Times New Roman"; font-size: 10.0pt; mso-ansi-language: EN-US; mso-bidi-language: AR-SA; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">Rheumatoid arthritis affects approximately one
out of every 100 people in the </span><span style="font-family: "Times New Roman"; font-size: 10.0pt; mso-ansi-language: EN-US; mso-bidi-language: AR-SA; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">United States</span><span style="font-family: "Times New Roman"; font-size: 10.0pt; mso-ansi-language: EN-US; mso-bidi-language: AR-SA; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">, occurring more frequently in older women than in
other population groups. The autoimmune disorder develops when the body’s
immune system wrongly targets its own joints, creating an inflammatory response
and often severe pain, which is usually localized in the small joints.
Different from osteoarthritis, RA affects the joints’ inner lining. This causes
swelling that can wear down the supporting bone structure and create
malformations in the joints.<br />
<br />
Researchers have not yet identified a definitive cause for rheumatoid
arthritis, although a combination of environmental and genetic factors is
likely responsible. They have pinpointed certain genetic markers associated
with chronic inflammation and an overly active engagement of the immune system
as exhibiting a tenfold potential to lead to the development of RA. Yet the
presence of these genes does not necessarily mean that a person will display
symptoms, and their absence cannot give assurance that he or she will never
develop the condition. <br />
<br />
In addition to its focus on attacking the joints, RA can occasionally affect
other areas of the body, such as the eyes, skin, blood vessels, and respiratory
system. Treatments for RA concentrate on alleviating pain and lessening the
potential for permanent damage to the joints.</span></span>Lindsay Rosenwaldhttp://www.blogger.com/profile/05813621454692272361noreply@blogger.comtag:blogger.com,1999:blog-5781709110777970831.post-52349496183994508392014-03-31T12:57:00.001-07:002014-03-31T12:57:57.273-07:00Smeal College of Business Researches Recalls and Brand Loyalty<div dir="ltr" style="text-align: left;" trbidi="on">
<div class="separator" style="clear: both; text-align: center;">
<a href="http://news.smeal.psu.edu/++theme++smeal.news-V1-4/static/smeal_logos/logo_smeal.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="http://news.smeal.psu.edu/++theme++smeal.news-V1-4/static/smeal_logos/logo_smeal.png" height="87" width="400" /></a></div>
<hr />
<hr />
<br />
<br />
<span style="color: #0c343d;">Consumers with high brand commitment, defined as people who are “attached to brands, form close relationships with them, and
have a general desire to maintain this close relationship,” may take a dimmer
view of product recalls than consumers with low brand commitment, according to
research published by Smeal College of Business professors in 2013. The
findings contradict the prevailing opinion that high brand loyalty helps
companies weather periods of negative publicity.</span><br />
<span style="color: #0c343d;"><br /></span>
<span style="color: #0c343d;">The Smeal researchers investigated consumer reactions to recalls in cases where
the products being called back could cause death or serious injury. They
discovered that high brand commitment was a liability in those situations.
Researchers speculated that consumers might feel more disappointed than usual
when a company they particularly like lets them down in such a way. The findings
did not hold in cases of low-severity recalls, in which the researchers
confirmed previous studies stating that brand loyalty tended to mitigate the
negative effects.</span></div>
Lindsay Rosenwaldhttp://www.blogger.com/profile/05813621454692272361noreply@blogger.comtag:blogger.com,1999:blog-5781709110777970831.post-9851270506001808492014-01-03T14:22:00.000-08:002014-01-03T14:22:02.483-08:00Charlie Rose Honored for Contributions to Medical Knowledge <div dir="ltr" style="text-align: left;" trbidi="on">
<span>A member of the Columbia-Presbyterian Hospital Health Sciences
Advisory Council, Dr. Lindsay Rosenwald has assisted in bestowing the
Council’s annual Award for Distinguished Service to individuals who have
significantly contributed to the health and well-being of society. A
physician and investor, Dr. Lindsay Rosenwald has spent much of his
career as the founder and backer of biotechnology companies that have
developed medicines that have greatly improved the health of many
patients.<br /><br />Numerous well-known individuals have received the
Advisory Council’s Award for Distinguished Service, including
Christopher Reeve, Mike Wallace, Anna Wintour, and Sanjay Gupta. In
2012, the award was given to Charlie Rose, a television personality and
anchor. Rose, who co-anchors the TV shows Charlie Rose on PBS and CBS
This Morning, worked with Nobel Prize winner Eric Kandel on PBS’ The
Brain Series. The series, which focused on the study of the human brain,
addressed topics such as aging, creativity, and social interaction. The
Brain Series also has examined the most current research into mental
illness, including Alzheimer’s disease and schizophrenia.
</span></div>
Lindsay Rosenwaldhttp://www.blogger.com/profile/05813621454692272361noreply@blogger.com0tag:blogger.com,1999:blog-5781709110777970831.post-45610505370056340692013-12-16T10:40:00.002-08:002013-12-16T10:40:23.014-08:00Abington Health Expands Services, Facilities<div dir="ltr" style="text-align: left;" trbidi="on">
<span>A physician and investor in the biotechnology field, Dr. Lindsay
Rosenwald began his medical training at the Temple University School of
Medicine. While starting his private medical practice, Dr. Lindsay
Rosenwald completed an internship at Abington Memorial Hospital in
Pennsylvania.<br /><br />The hospital is now the flagship facility of
Abington Health, a not-for-profit regional health care provider that
consistently offers innovative and advanced care to its patients.
Abington Health’s providers assist more than 700,000 patients annually,
and the health care system employs in excess of 1,200 physicians.
Abington Health has earned Comprehensive Stroke Center certification
from the Joint Commission and the American Heart Association/American
Stroke Association.<br /><br />Recently, the provider installed the
latest-generation MR system, which offers patients a better MR scan
experience and produces high-resolution images that help physicians to
make more accurate diagnoses. Furthermore, the health care system added a
fourth outpatient center. The new 48,000-square-foot facility houses
outpatient services and several doctors’ practices that provide care for
a wide range of patients, ranging from newborns to senior citizens. The
center encompasses a laboratory draw site and an imaging center.
</span></div>
Lindsay Rosenwaldhttp://www.blogger.com/profile/05813621454692272361noreply@blogger.com0tag:blogger.com,1999:blog-5781709110777970831.post-35045891692607815552013-12-10T14:46:00.001-08:002013-12-10T14:46:21.714-08:00Early Biotechnology IPOs Led to Greater Growth <div dir="ltr" style="text-align: left;" trbidi="on">
<span>As one of the first physician analysts on Wall Street, Dr. Lindsay
Rosenwald came to the biotechnology marketplace with a strong
understanding of what would benefit medicine in general and secure
profits at the same time. Entering the world of biotechnology investment
in the mid-1980s, Dr. Lindsay Rosenwald built upon a precedent largely
set by Genentech, SmithKline, and other innovative biotech firms 10
years earlier.</span><br />
<span><br />With SmithKline’s development of Tagamet (the
first-ever “blockbuster drug” with $1 billion in annual revenue) and
Genentech’s advances in rDNA technology, the mid-1970s proved a fertile
ground for the nascent biotech sector. When Genentech launched a highly
successful initial public offering in 1980, opening itself to investment
on Wall Street became the next logical step for innovators in the life
sciences, followed by other, early IPOs Cetus, Applied Biosystems, and
Amgen. At the same time, much larger pharmaceutical companies began
acquiring promising biotech firms that had yet to go public, creating
multiple pathways for these new drug developers to grow and expand.
</span></div>
Lindsay Rosenwaldhttp://www.blogger.com/profile/05813621454692272361noreply@blogger.com0tag:blogger.com,1999:blog-5781709110777970831.post-77597527753920370712013-12-02T14:11:00.001-08:002013-12-02T14:11:08.818-08:00Amgen Moves into Cancer Treatment with Purchase of Onyx<div dir="ltr" style="text-align: left;" trbidi="on">
<!--[if gte mso 9]><xml>
<w:WordDocument>
<w:View>Normal</w:View>
<w:Zoom>0</w:Zoom>
<w:Compatibility>
<w:BreakWrappedTables/>
<w:SnapToGridInCell/>
<w:WrapTextWithPunct/>
<w:UseAsianBreakRules/>
</w:Compatibility>
<w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel>
</w:WordDocument>
</xml><![endif]--><br />
<div class="separator" style="clear: both; text-align: center;">
<a href="http://www.pizaazz.com/wp-content/uploads/2010/03/amgen_logo_03.jpg" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"><img border="0" src="http://www.pizaazz.com/wp-content/uploads/2010/03/amgen_logo_03.jpg" /></a></div>
<!--[if gte mso 10]>
<style>
/* Style Definitions */
table.MsoNormalTable
{mso-style-name:"Table Normal";
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-parent:"";
mso-padding-alt:0in 5.4pt 0in 5.4pt;
mso-para-margin:0in;
mso-para-margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-size:10.0pt;
font-family:"Times New Roman";}
</style>
<![endif]--><span style="font-family: "Times New Roman"; font-size: 12.0pt; mso-ansi-language: EN-US; mso-bidi-language: AR-SA; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;"></span><br />
<span style="font-family: "Times New Roman"; font-size: 12.0pt; mso-ansi-language: EN-US; mso-bidi-language: AR-SA; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">New York City-based biotech financier Lindsay
Rosenwald, MD, possesses over 20 years of experience in investing in health
care and life sciences companies. In 2008, Lindsay Rosenwald co-founded Opus
Point Partners to create a premier investment fund focused on biotechnology.<br />
<br />
After several months of discussion, Amgen Inc. agreed to buy Onyx
Pharmaceuticals Inc. in a transaction valued at $10.4 billion. The deal will
bolster Amgen's product line with Onyx's slate of cancer-fighting drugs,
including Kyprolis, a treatment for a form of blood cancer. Until this
acquisition, Amgen had mainly produced drugs aimed at supporting rather than
treating cancer patients. Because the population is aging and the oncology
market is expected to grow as a result, Amgen's purchase of Onyx is widely
considered a sound, forward-looking move.<br />
<br />
This buyout is the latest in a pharmaceuticals industry in which numerous
established firms have sufficient cash on hand to acquire smaller companies.
From an investment perspective, this market environment offers many
opportunities for investors in small, innovative companies to see their stakes
rise dramatically in value as larger firms seek to enhance their product portfolios.</span></div>
Lindsay Rosenwaldhttp://www.blogger.com/profile/05813621454692272361noreply@blogger.com0tag:blogger.com,1999:blog-5781709110777970831.post-55023997319788333982013-11-25T10:36:00.002-08:002013-11-25T10:37:55.878-08:00Bullish Biotech a Boon to Health Sector Investors<div dir="ltr" style="text-align: left;" trbidi="on">
<div class="separator" style="clear: both; text-align: center;">
<a href="http://wire.kapitall.com/wp-content/image-import/1564163641-430x323.jpg" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"><img border="0" height="150" src="http://wire.kapitall.com/wp-content/image-import/1564163641-430x323.jpg" width="200" /></a></div>
<!--[if gte mso 9]><xml>
<w:WordDocument>
<w:View>Normal</w:View>
<w:Zoom>0</w:Zoom>
<w:Compatibility>
<w:BreakWrappedTables/>
<w:SnapToGridInCell/>
<w:WrapTextWithPunct/>
<w:UseAsianBreakRules/>
</w:Compatibility>
<w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel>
</w:WordDocument>
</xml><![endif]--><br />
<!--[if gte mso 10]>
<style>
/* Style Definitions */
table.MsoNormalTable
{mso-style-name:"Table Normal";
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-parent:"";
mso-padding-alt:0in 5.4pt 0in 5.4pt;
mso-para-margin:0in;
mso-para-margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-size:10.0pt;
font-family:"Times New Roman";}
</style>
<![endif]-->
<br />
<div class="MsoNormal">
As the co-founder of Opus Point Partners, Lindsay Rosenwald,
MD, devotes his considerable expertise as a physician and entrepreneur to
managing one of Wall Street's top biotechnology-focused investment funds. Top
investors like Lindsay Rosenwald have taken serious notice of the very bullish
biotechnology sector this year. <br />
<br />
</div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
A number of biotechnology acquisitions have been announced in the past few
months, including:</div>
<br />
<blockquote class="tr_bq">
- Valeant Pharmaceuticals International agreed to buy Bausch + Lomb for $8.7
billion, greatly expanding Valeant's eye care business. </blockquote>
<blockquote>
<div class="MsoNormal">
<br />
- Actavis Inc., which manufactures generic drugs, announced the purchase of
Warner Chilcott in an $8.5 billion transaction.</div>
<div class="MsoNormal">
<br />
- Thermo Fisher Scientific, a maker of scientific instruments, acquired another
instrument manufacturer, Life Technologies, for $13.6 billion.</div>
<br />
<span style="font-family: "Times New Roman"; font-size: 12.0pt; mso-ansi-language: EN-US; mso-bidi-language: AR-SA; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">
- Amgen announced a deal worth $10.4 billion to buy Onyx and its line of cancer
treatments.</span><br />
<span style="font-family: "Times New Roman"; font-size: 12.0pt; mso-ansi-language: EN-US; mso-bidi-language: AR-SA; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;"></span></blockquote>
<span style="font-family: "Times New Roman"; font-size: 12.0pt; mso-ansi-language: EN-US; mso-bidi-language: AR-SA; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">
<br />
Typically, a buyout forces the purchasing company's stock price to drop and the
acquired company's price to spike. In recent biotech acquisitions, however,
both parties' stock prices have risen, suggesting strong investor confidence in
the sector. This attitude is further reflected in the recent positive
performance of many biotechnology exchange traded funds (ETFs), which track
along with sector-wide trends.<br />
<br />
Many analysts believe this positive trend will continue as large firms seek to
buy out small, agile companies with innovative new products. Given the aging
trends in the populations of developed nations, investing in life sciences
today would appear to be a good bet for the long term.</span></div>
Lindsay Rosenwaldhttp://www.blogger.com/profile/05813621454692272361noreply@blogger.com0tag:blogger.com,1999:blog-5781709110777970831.post-83503278921165713042013-11-18T13:22:00.001-08:002013-11-18T13:22:17.433-08:00 Biotechs Experience Success after Initial Public Offering <div dir="ltr" style="text-align: left;" trbidi="on">
<span>The co-founder of the New York City asset management firm Opus
Point Partners, Lindsay Rosenwald has built a career around
biotechnology investment. Since the 1980s, Lindsay Rosenwald has
identified investment opportunities in the medical sector, having served
as one of Wall Street's first physician analysts.<br /><br />As of July
2013, 16 biotechnology companies have gone public this year, with more
than half a dozen companies completing initial public offerings in June
alone. Share prices for these firms are now at an average of 48 percent
higher than their offering prices. This jump is due in part to Onyx
Pharmaceuticals' recent refusal of a $120 per share buyout offer from
international giant Amgen. Onyx's demand for a higher price launched a
wave of stock increases for biotechs across the country. In mid-July,
the New York Times reported that "four of the top 10 performing
companies on the Nasdaq year-to-date were biotechs."<br /><br />In addition,
larger companies have acquired venture-capital-backed biotechs. In the
second quarter alone, industry leaders bought out five such firms.
Moreover, pharmaceutical companies often target small biotechs as
licensing partners, saving themselves the upfront investment in research
and development.
</span></div>
Lindsay Rosenwaldhttp://www.blogger.com/profile/05813621454692272361noreply@blogger.com0tag:blogger.com,1999:blog-5781709110777970831.post-1413907230457595112013-10-21T15:45:00.001-07:002013-10-21T15:45:32.125-07:00Pharmaceutical and Biotech Sectors Experience Surge in China<div class="separator" style="clear: both; text-align: center;">
<a href="http://2.bp.blogspot.com/-rcWlvaZbNnU/UmWugL53U6I/AAAAAAAAAFA/eJRtO8Hajm4/s1600/images.jpg" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"><img border="0" height="144" src="http://2.bp.blogspot.com/-rcWlvaZbNnU/UmWugL53U6I/AAAAAAAAAFA/eJRtO8Hajm4/s200/images.jpg" width="200" /></a></div>
<span>Over the last two decades, Lindsay Rosenwald has funded an array
of small biotechnology firms, and he has sold several of these companies
to large pharmaceutical corporations. Today, Lindsay Rosenwald draws on
this experience in his work as co-manager of the asset management firm
Opus Point Partners in New York City.<br /><br />In recent years, health
care spending has increased dramatically in China. In 2006, only 43
percent of the Chinese population had health insurance, and the average
health care spending per person was $119. Five years later, 95 percent
of the population had health insurance, and spending had jumped to $261
per person. <br /><br />In response to the country’s increasing commitment
to health care, pharmaceutical companies have started making inroads in
the Chinese market. Major firms such as Sanofi, Novo Nordisk A/S, and
Eli Lilly and Company have helped grow the pharmaceutical market size to
more than $71 billion. Additionally, these corporations are
collaborating with and investing in an array of local partners.<br /><br />China
also boasts a burgeoning biotechnology industry; thanks to more than
$160 billion in investments, the sector has developed 12 new drugs.
Presently, the country is focused primarily on producing therapies to
treat cancer, and it places a significant emphasis on biologics rather
than small molecule drugs. By 2020, officials hope to bring 100 new
therapies to market.
</span>Lindsay Rosenwaldhttp://www.blogger.com/profile/05813621454692272361noreply@blogger.com0tag:blogger.com,1999:blog-5781709110777970831.post-11233538735088282272013-10-08T16:12:00.003-07:002013-10-16T12:50:47.399-07:00 Pharmas Report Initial Successes with New Heart Disease Biotherapy <div dir="ltr" style="text-align: left;" trbidi="on">
<div class="separator" style="clear: both; text-align: center;">
<a href="http://2.bp.blogspot.com/-5qHliSLMmJs/UlSRWu4lIeI/AAAAAAAAADc/cytkH_YN2SM/s1600/250px-Protein_PCSK9_PDB_2p4e.png" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"><img border="0" height="170" src="http://2.bp.blogspot.com/-5qHliSLMmJs/UlSRWu4lIeI/AAAAAAAAADc/cytkH_YN2SM/s200/250px-Protein_PCSK9_PDB_2p4e.png" width="200" /></a></div>
A physician and biotechnology investor, Lindsay Rosenwald has
helped to fund drugs for leukemia and prostate cancer. Today, Lindsay
Rosenwald co-manages a New York City asset
management firm that focuses on medical innovation.<br /><br />Over the last
decade, researchers have made a series of major discoveries that have
given pharmaceutical and biotechnology firms a better understanding of
the biological causes of high cholesterol. Due to this extraordinary
research, which showed that various mutations of a gene called <a href="http://en.wikipedia.org/wiki/PCSK9">PCSK9</a>
dramatically affect low-density lipoprotein (LDL) cholesterol levels,
drug developers have begun a race for what could be a cure for heart
disease. <br /><br />Currently, pharmaceutical giants Amgen Inc., Pfizer
Inc., and Sanofi each have drugs in clinical trials. Comprised of
monoclonal antibodies derived from living cells, these new therapies
mimic the effects of the mutated PCSK9 gene. Patients currently
participating in the clinical trials have responded well to the injected
drug, demonstrating drastically lower LDL levels. Although the drugs
will not likely receive approval from the U.S. Food and Drug
Administration for several years, Amgen has already built three
facilities to produce its cholesterol drug once it is ready for market.
</div>
Lindsay Rosenwaldhttp://www.blogger.com/profile/05813621454692272361noreply@blogger.com0tag:blogger.com,1999:blog-5781709110777970831.post-6201957962745453882013-09-25T15:12:00.002-07:002013-10-16T12:51:41.291-07:00 Smeal College of Business on Final Stretch of Five-Year Strategic Plan <div dir="ltr" style="text-align: left;" trbidi="on">
<div class="separator" style="clear: both; text-align: center;">
<a href="http://2.bp.blogspot.com/-amBucMkV_bM/UkNftXT7evI/AAAAAAAAADI/SbrMxrN6gUU/s1600/images.jpg" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"><img border="0" height="114" src="http://2.bp.blogspot.com/-amBucMkV_bM/UkNftXT7evI/AAAAAAAAADI/SbrMxrN6gUU/s320/images.jpg" width="320" /></a></div>
Dr. Lindsay Rosenwald co-leads a New York
City asset management firm focused primarily on biotechnology
investment. A graduate of The Pennsylvania State University and the
Temple University School of Medicine, Dr. Lindsay Rosenwald holds a seat
on the Board of Visitors of Penn State's Smeal College of Business.<br /><br />In
2008, the Smeal College of Business at The Pennsylvania State
University introduced a five-year strategic plan that focused in on four
core principles: extraordinary education, research with impact,
dialogue with society, and community with distinction. Within each of
these categories, officials identified an array of measurable goals,
ranging from creating a new major to increasing research endowments to
boosting mentorship programs. The Smeal College of Business developed
these strategic goals with the ultimate objective of becoming one of the
top five business schools in the nation.<br /><br />Over the last five
years, the Smeal College of Business has demonstrated its commitment to
continued success and improvement. As the plan comes to an end with the
close of 2013, officials will analyze the overall effectiveness of the
initiative and its goals. To learn more about this school's educational
programming for undergraduate, graduate, and executive students, please
visit <a href="http://smeal.psu.edu/">Smeal.PSU.edu</a>.
</div>
Lindsay Rosenwaldhttp://www.blogger.com/profile/05813621454692272361noreply@blogger.com0tag:blogger.com,1999:blog-5781709110777970831.post-19927277253211570572013-09-19T20:56:00.002-07:002013-09-19T20:56:51.993-07:00 Two Basic Differences between Biotech and Pharmaceutical Firms <div dir="ltr" style="text-align: left;" trbidi="on">
<span>A New York City-based investment professional, Dr. Lindsay
Rosenwald co-heads an asset management hedge fund dedicated primarily to
the biotechnology sector. Over the course of his career, Dr. Lindsay
Rosenwald has played a role in developing drugs to treat prostate
cancer, influenza, and rheumatoid arthritis.<br /><br />Although the work of
biotechnology and pharmaceutical companies often overlaps, several
major differences actually exist between the sectors. This article will
discuss two such distinctions. <br /><br />Firstly, <a href="http://en.wikipedia.org/wiki/Biotechnology">biotechnology </a>firms
typically work with complex proteins, genetic material, and
microorganisms. Rather than using chemical-based synthetic processes to
develop small-molecule drugs, as pharmaceutical companies do,
biotechnology firms focus their research on the discovery of novel
compounds that can be applied to various therapies.<br /><br />Secondly,
biotechnology companies often operate at a loss during their extensive
research and development phases; however, by taking this risk in
R&D, they are often responsible for creating the most innovative
drugs on the market. On the other hand, pharmaceutical companies
generally invest more in marketing and sales, and can use the funds from
current drugs on the market to subsidize new research or to license new
drugs from organizations like biotechnology firms. Upon creating a
successful drug or therapy, many biotechnology firms collaborate with
larger pharmaceutical companies that have a marketing and sales
infrastructure in place, licensing the drug to or even merging with the
larger firm.
</span></div>
Lindsay Rosenwaldhttp://www.blogger.com/profile/05813621454692272361noreply@blogger.com0tag:blogger.com,1999:blog-5781709110777970831.post-25894573002841017742013-01-31T14:30:00.003-08:002013-09-25T15:13:54.078-07:00From Wall Street to Biotech<div dir="ltr" style="text-align: left;" trbidi="on">
A biotechnology and life-sciences investor with numerous
achievements in his field, Lindsay Rosenwald serves as one of two
founding partners of Opus Point Partners, an asset management firm in
the healthcare sector. Raised in Pennsylvania, Dr. Rosenwald graduated
from Abington Senior High School before enrolling at Penn State
University, where he pursued studies in finance and economics. An
outstanding student and member of the Beta Gamma Sigma honor society,
Lindsay Rosenwald graduated from Penn State with a Bachelor of Science
in 1976 and subsequently became an independent management consultant for
the burgeoning healthcare industry. From there, he gained admission to
the Temple University School of Medicine, earned his Doctor of Medicine
in 1983, and completed his clinical training in internal medicine at
Abington Memorial Hospital. After a period in private practice, Lindsay
Rosenwald returned to the business world and began a prolific career in
the investment and management of promising drug development companies.<br />
<br />
Having
worked on Wall Street in the mid-1980s, Lindsay Rosenwald became a
hugely successful venture capitalist in the Biotech space. To date, Dr.
Rosenwald and his companies have licensed and further developed over one
hundred drug candidates. More information on Lindsay Rosenwald and his
work can be found at <a href="http://www.linkedin.com/in/lindsayrosenwald">www.linkedin.com/in/lindsayrosenwald</a>. </div>
Lindsay Rosenwaldhttp://www.blogger.com/profile/05813621454692272361noreply@blogger.com0